| Name | Title | Contact Details |
|---|
Oski`s unique formal verification services deliver peak sign-off confidence earlier in the development cycle by diving deep into design behavior to track down the most complex corner-case bugs. Our approach exhaustively proves the absence of bugs and brings a higher level of productivity to our clients, as compared with traditional simulation and formal verification approaches. Since 2005, Oski has focused on developing comprehensive formal verification methodologies to identify and sign-off high-risk blocks, achieve system-level architecture sign-off, and quickly resolve post-silicon bugs. Oski has built the largest team of formal verification experts in the world. Our founder and Chief Oski, Vigyan Singhal, did his PhD thesis at UC Berkeley in formal methods of verification. Vigyan later developed Cadence`s first-generation formal verification tool, and was the founder of Jasper Design Automation, which was later acquired by Cadence. The company is headquartered in San Jose, CA with a design center in Gurugram, India.
eSys Distribution, Inc. is a Glendale Heights, IL-based company in the Computers & Electronics sector.
Weidmuller is a Richmond, VA-based company in the Computers and Electronics sector.
Logue Industries Inc is a El Centro, CA-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.